Table 3.
.
| Type of abnormal finding | Total number (n) | Abnormality started after dupilumab n, (%) | Severity if occurred after dupilumab or unknown n, (%) | Relative duration if occurred after dupilumab or unknown n, (%) | |||||
|---|---|---|---|---|---|---|---|---|---|
| Yes | Unknown | Mild | Moderate | Severe | Transient | Persistent | Unknown | ||
| Eosinophilia | 82 | 24 (29) | 0 | 23 (96) | 1 (4) | 0 | 15 (63) | 8 (33) | 1 (4) |
| Other FBC abnormalitiesa | 53 | 15 (28) | 3 (6) | 16 (100) | 0 | 0 | 11 (61) | 2 (11) | 5 (28) |
| Anaemia | 2 (100) | 0 | 0 | 2 (100) | 0 | 0 | |||
| Basophilia | 7 (100) | 0 | 0 | 5 (71) | 0 | 2 (29) | |||
| Microcytosis | N/A | N/A | N/A | 0 | 1 (50) | 1 (50) | |||
| Lymphopaenia | 3 (100) | 0 | 0 | 2 (67) | 0 | 1 (33) | |||
| Neutrophilia | 1 (100) | 0 | 0 | 0 | 1 (100) | 0 | |||
| Thrombocytopaenia | 3 (100) | 0 | 0 | 2 (67) | 0 | 1 (33) | |||
| U&E abnormalitiesb | 55 | 6 (11) | 0 | 4 (67) | 1 (11) | 1 (11) | 6 (100) | 0 | 0 |
| Reduced eGFR | 4 (67) | 1 (11) | 1 (11) | 6 (100) | 0 | 0 | |||
| Abnormal LFTs | 67 | 18 (12) | 1 (1) | 16 (89) | 2 (11) | 0 | 13 (72) | 3 (17) | 2 (11) |
| Raised bilirubin | 3 (100) | 0 | 0 | 2 (67) | 0 | 1 (33) | |||
| Increased ALP | 1 (100) | 0 | 0 | 1 (100) | 0 | 0 | |||
| Increased ALT | 9 (82) | 2 (18) | 0 | 9 (82) | 2 (18) | 0 | |||
| Increased GGT | 2 (100) | 0 | 0 | 0 | 1 (50) | 1 (50) | |||
| HbA1c raised | 2 | 0 | 0 | N/A | N/A | N/A | N/A | N/A | N/A |
| Lipid profile abnormalities | 3 | 0 | 2 | 2 (100) | 0 | 0 | 0 | 0 | 2 (100) |
| Connective tissue disease screen positive | 5 | 0 | 2 | N/A | N/A | N/A | 0 | 0 | 2 |
| Raised CRP | 1 | 1 | 0 | 1 (100) | 0 | 0 | 1 (100) | 0 | 0 |
| Raised total IgE | 1 | 0 | 1 | N/A | N/A | N/A | 0 | 0 | 1 (1) |
| Total | 269 | 64 (24) | 9 (3) | 62 (93) | 4 (6) | 1 (1) | 46 (64) | 13 (18) | 13 (18) |
This table summarises laboratory abnormalities identified during laboratory screening and monitoring for dupilumab (n = 149). Severity and duration data is presented for abnormalities that developed after dupilumab onset (normal result within 1 year prior to dupilumab), or where there is no prior corresponding test result within 1 year of starting dupilumab. See Table S1 in the Electronic Supplementary materials for severity criteria for laboratory abnormalities. The following definitions were used when describing the duration of laboratory abnormalities: transient—resolved while still taking dupilumab, persistent—abnormality persisted (on at least one repeat laboratory test) while patient was still receiving dupilumab, unknown—no repeat blood tests available. a additional FBC abnormalities not summarised in this table included macrocytosis and thrombocytosis, b additional U&E abnormalities not summarised in this table included elevated urea and electrolyte derangements